Literature DB >> 10233228

Childhood vulval pemphigoid: a clinical and immunopathological study of five patients.

A M Farrell1, G Kirtschig, K L Dalziel, J Allen, G Dootson, S Edwards, F Wojnarowska.   

Abstract

We describe five girls with vulval pemphigoid: two had bullous pemphigoid confined to the vulva and three had cicatricial pemphigoid. They demonstrate a spectrum of severity from localized disease to extensive vulval scarring necessitating long-term immunosuppressive therapy and surgical correction. The age at onset of their disease ranged between 6 and 13 years. All presented with vulval discomfort and erosions. Three had oral lesions, two perianal and one eye and cutaneous involvement. Two girls with only vulval lesions and one with vulval and oral lesions responded well to topical steroids. In two, systemic treatment with prednisolone and dapsone or azathioprine was required. The diagnosis was made on the basis of histology and immunofluorescence (IF). All had positive direct IF with IgG and C3. Indirect IF demonstrated circulating IgG binding to the basement membrane zone in four, with dermal or epidermal binding on salt-split skin substrate. Immunoblotting revealed antibodies to the BP230 and BP180 antigens. Immunoelectron microscopy in the child with dermal binding IgG and BP180 and BP230 on immunoblotting showed labelling at the lamina densa-lamina lucida interface adjacent to hemidesmosomes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233228     DOI: 10.1046/j.1365-2133.1999.02668.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

1.  Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 2.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  [Blistering autoimmune diseases of childhood].

Authors:  M Goebeler; D Zillikens
Journal:  Hautarzt       Date:  2002-12-20       Impact factor: 0.751

4.  Vesicobullous disorders of female genitalia.

Authors:  Taru Garg; Saurabh Mittal
Journal:  Indian J Sex Transm Dis AIDS       Date:  2012-01

5.  Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient.

Authors:  Erin N Wilmer; Nils Becker; Allison Chen; George Kroumpouzos
Journal:  JAAD Case Rep       Date:  2016-01-22

6.  Localised childhood vulvar pemphigoid: a rare case study.

Authors:  A S Peeters; N Dhont; H Stals
Journal:  Facts Views Vis Obgyn       Date:  2021-09

Review 7.  Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment.

Authors:  Angelo Ruggiero; Matteo Megna; Alessia Villani; Rosita Comune; Gabriella Fabbrocini; Francesca di Vico
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-04-14

8.  Juvenile and adult vulvar pemphigoid, an under recognized entity: Case series of fourteen patients.

Authors:  Hanan Rashid; J Marja Oldhoff; Martha Esajas; Gilles F H Diercks; Hendri H Pas; Maria C Bolling; Barbara Horváth
Journal:  JAAD Case Rep       Date:  2021-05-24

9.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.